20 Mar 2019
Posted in Pharma
HeartMate 3 has potential to significantly impact treatment options for patients with end stage heart failure
Results posted from the MOMENTUM-3 clinical trial at the 68th American College of Cardiology Scientific Session on 17 March 2019, revealed that the HeartMate 3 LVAD demonstrated superiority over the HeartMate 2 LVAD in long-term treatment of end stage heart failure. David Brown, Medical Devices Analyst at GlobalData, offers his view:
“The results of the MOMENTUM-3 trial are promising as they demonstrate that further engineering on behalf of medical device manufacturers can produce a significant and positive impact on the treatment options for patients with end stage heart failure. LVADs comprise ~82% of the global Mechanical Circulatory Assist market and this is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.8%.
“Abbott’s MagLev pump technology in the HeartMate 3, which is responsible for the reduction of many severe complications, has now established the device as a clear choice for patients that are not suitable for heart transplantation and do not respond to other treatments. Abbott’s HeartMate 3 LVAD device has also demonstrated reduced hospitalization time and vastly reduced blood clotting.
“These combined findings are an important step towards reducing the costs associated with end stage heart failure management and will drive the adoption of the implantable HeartMate 3 in developed and developing countries alike.”